hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06284538 id: NA-01-23 briefTitle: Study to Evaluate the Effectiveness of a Medical Device Based on Hyaluronic Acid in Wounds acronym: WOUND-H overallStatus: RECRUITING date: 2024-01-15 date: 2024-07-31 date: 2024-09-30 date: 2024-02-29 date: 2024-02-29 name: Nova Argentia S.r.l. class: INDUSTRY briefSummary: The primary objective of the study is to evaluate the safety and performance of a Class IIB medical device based on linear hyaluronic acid used in the treatment of post-surgical wounds. The outcomes of the study are the improvement of wound healing assessed through the Clinical Healing score (score from 0 to 5), which includes the evaluation of: redness, edema, suppuration, healthy granulation tissue and signs of re-epithelialization; the percentage of patients with completely healed wounds at day 30 post-treatment; the pain perceived by the patient when changing the dressing; the frequency of adverse events. conditions: Wound Healing Disorder studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 112 type: ESTIMATED name: NOVA.EMOSTOP RE-EPITHELIZING measure: improvement in Clinical Healing score at visit 3 sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Casa di cura riabilitativa Villa Sofia status: RECRUITING city: Acireale state: Catania zip: 95024 country: Italy name: Marco Daniele, PI role: CONTACT phone: 0957631997 email: marcodaniele@email.it name: Salvatore Balsamo role: SUB_INVESTIGATOR lat: 37.60886 lon: 15.16577 typeAbbrev: Prot_SAP hasProtocol: True hasSap: True hasIcf: False label: Study Protocol and Statistical Analysis Plan date: 2023-06-26 uploadDate: 2024-02-13T04:55 filename: Prot_SAP_000.pdf size: 2091803 typeAbbrev: ICF hasProtocol: False hasSap: False hasIcf: True label: Informed Consent Form date: 2023-04-02 uploadDate: 2024-02-21T04:35 filename: ICF_001.pdf size: 95177 hasResults: False
nctId: NCT06284525 id: 2137420 briefTitle: Ankle Assistance and Resistance in Older Adults overallStatus: RECRUITING date: 2023-02-01 date: 2025-01 date: 2025-01 date: 2024-02-29 date: 2024-02-29 name: Northern Arizona University class: OTHER briefSummary: The goal of this research protocol is to improve mobility in older individuals through advances in wearable assistive devices by focusing on two specific aims. The first aim is to study if targeted ankle resistance gait training improves walking performance in older individuals. The second aim is to evaluate the potential of wearable assistance at the ankle, knee, and/or hip joints to increase walking performance in older individuals. conditions: Sarcopenia studyType: INTERVENTIONAL phases: EARLY_PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 8 type: ESTIMATED name: Ankle resistance and biofeedback measure: 6MWT measure: Metabolic power measure: Plantar flexor strength sex: ALL minimumAge: 65 Years maximumAge: 85 Years stdAges: OLDER_ADULT facility: Northern Arizona University status: RECRUITING city: Flagstaff state: Arizona zip: 86011 country: United States name: Zach Lerner, PhD role: CONTACT phone: 928-523-1787 email: zachary.lerner@nau.edu lat: 35.19807 lon: -111.65127 hasResults: False
nctId: NCT06284512 id: Uveal Melanoma 1942/2022 briefTitle: Uveal Melanoma - Comparative Study overallStatus: RECRUITING date: 2023-10-15 date: 2024-12-31 date: 2024-12-31 date: 2024-02-29 date: 2024-02-29 name: Medical University of Vienna class: OTHER briefSummary: The progress of uveal melanoma is typically monitored with sonography by experienced onco-ophthalmologists. However, there is evidence that twodimensional measurements in color fundus photography match precisely with sonography measurements. This study aims to compare sonography and color fundus photography measurements in order to evaluate the feasibility of monitoring of uveal melanoma with color fundus photography. conditions: Uveal Melanoma studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 50 type: ESTIMATED name: Sonography, color fundus photography measure: Largest Basal Diameter sex: ALL minimumAge: 18 Years maximumAge: 99 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Medical University of Vienna, Department of Ophthalmology and Optometry status: RECRUITING city: Vienna zip: 1090 country: Austria name: Judith Kreminger, MD role: CONTACT phone: +4314040048470 email: judith.kreminger@meduniwien.ac.at name: Reinhard Told, MD, PhD, Priv.-Doz. role: CONTACT phone: +434040079690 email: reinhard.told@meduniwien.ac.at name: Adrian Reumueller, MD, Priv.-Doz role: SUB_INVESTIGATOR name: Roman Dunavölgyi, Assoc.-Prof. Priv.-Doz. Dr. role: SUB_INVESTIGATOR lat: 48.20849 lon: 16.37208 hasResults: False
nctId: NCT06284499 id: 26308819120 briefTitle: Effect of Different Fixed Lingual Retainers on Tooth Stability overallStatus: WITHDRAWN date: 2020-01-16 date: 2023-01-15 date: 2023-10-13 date: 2024-02-29 date: 2024-02-29 name: Mustafa Kemal University class: OTHER briefSummary: Objective: The aim of this study was to compare the effect of different fixed lingual retainers (LRs) on tooth stability after orthodontic treatment using a Periotest® device.
Materials and methods: A total of 82 patients (43 females and 39 males; mean age = 18.61 ± 3.71 years) with no missing teeth in the lower inter-canine region were treated with fixed orthodontic mechanics. At the completion of the orthodontic treatment, each patient was fitted with either Ortho FlexTech (Reliance; Group I), dead soft 8-braided (Bond-A-Braid, Reliance; Group II), or 5-stranded (PentaOne, Masel; Group III) LR wire. A control group consisting of people with a healthy periodontal condition and no bone loss was included (Control; Group C). The mobility of the lower anterior teeth on the right and left sides was measured using a Periotest® device before (T0), immediately after (T1), and 10 months after (T2) the application of the LR. Statistical analyses were performed using one-way ANOVA followed by post hoc LSD, repeated ANOVA with Bonferroni post hoc test, and Pearson χ2 tests. conditions: Effect of Lingual Retainers on Tooth Stability studyType: OBSERVATIONAL observationalModel: CASE_CROSSOVER timePerspective: PROSPECTIVE count: 0 type: ACTUAL name: measuring tooth stability after orthodontic treatment using a Periotest® device. measure: Assessment of tooth stability after orthodontic lingual retainer wire application using periotest device sex: ALL minimumAge: 14 Years maximumAge: 20 Years stdAges: CHILD stdAges: ADULT facility: Hatay Mustafa Kemal University, Faculty of Dentistry city: Hatay zip: 31060 country: Turkey lat: 38.40227 lon: 27.10486 hasResults: False
nctId: NCT06284486 id: 2023-0794 id: NCI-2024-01721 type: OTHER domain: NCI-CTRP Clinical Registry briefTitle: A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib overallStatus: NOT_YET_RECRUITING date: 2024-07-31 date: 2026-12-30 date: 2028-12-30 date: 2024-02-29 date: 2024-03-27 name: M.D. Anderson Cancer Center class: OTHER name: Syndax Pharmaceuticals name: Break Through Cancer name: AbbVie briefSummary: To learn if the combination of venetoclax and revumenib can help to control MRD-positive AML. conditions: Acute Myeloid Leukemia studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 8 type: ESTIMATED name: Venetoclax name: Revumenib measure: Safety and adverse events (AEs) sex: ALL minimumAge: 12 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: MD Anderson Cancer Center city: Houston state: Texas zip: 77030 country: United States name: Ghayas Issa, MD role: CONTACT phone: 713-745-6798 email: gcissa@mdanderson.org name: Ghayas Issa, MD role: PRINCIPAL_INVESTIGATOR lat: 29.76328 lon: -95.36327 hasResults: False
nctId: NCT06284473 id: 212154 briefTitle: Ketamine as a Supplement to Local Anesthesia for Minor Procedures acronym: INK-MP overallStatus: RECRUITING date: 2022-05-25 date: 2025-05-31 date: 2025-05-31 date: 2024-02-29 date: 2024-03-15 name: Loyola University class: OTHER briefSummary: This trial is a double-blind randomized controlled clinical trial of adults and children (ages 7 to less than 70 years). Patients who present to the ED and who undergo minor bedside procedures that require local anesthesia will be divided into two groups: The first group will be treated with 0.7 mg/kg intranasal ketamine as well as standard local anesthesia for the procedure (treatment cohort). The second group will be treated with a volume-based dose of intranasal saline solution as well as standard local anesthesia for the procedure (control cohort). The primary aim is to assess whether patients in the treatment cohort report lower pain scores on the Numerical Rating Scale (NRS-100) when compared to patients in the control cohort. For adult patients, a secondary aim is to compare agitation between the two cohorts using the Richmond Agitation Sedation Scale (RASS) and, for pediatric patients, a secondary aim is to compare alertness between the two cohorts using the University of Michigan Sedation Scale (UMSS).
Results obtained from specific procedures will be analyzed on a spectrum of complexity and general length of recovery time. Scientific achievements may include finding a safe and effective way to reduce pain and discomfort during minor procedures in the Emergency Department. Additionally, it would provide opportunities for more research on sub-dissociative doses of ketamine during minor procedures: a topic in which there is still a gap in the published research conditions: Pain, Procedural conditions: Minor Laceration conditions: Abscess studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Patients presenting to the emergency department at Loyola University Medical Center for a minor medical procedure requiring local anesthesia will be randomly assigned to receive either standard local anesthesia with 0.7 mg/kg intranasal ketamine before the procedure or to standard local anesthesia with volume-based dose saline before the procedure using a 1:1 random block allocation. primaryPurpose: TREATMENT masking: QUADRUPLE maskingDescription: All participants and study personnel are blinded except for the clinical pharmacist who prepares the intervention. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 108 type: ESTIMATED name: Ketamine name: Saline measure: Immediate pain measure: Acute pain measure: Delayed pain measure: Immediate agitation measure: Acute agitation measure: Delayed agitation measure: Immediate alertness measure: Acute alertness measure: Delayed alertness sex: ALL minimumAge: 7 Years maximumAge: 70 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Loyola University Medical Center status: RECRUITING city: Maywood state: Illinois zip: 60153 country: United States name: Shannon Lovett, MD role: CONTACT phone: 847-951-2936 email: slovett@lumc.edu name: Trent Reed, DO role: CONTACT phone: 708-216-4117 email: treed1@lumc.edu lat: 41.8792 lon: -87.84312 hasResults: False
nctId: NCT06284460 id: 2022-0622 id: NCI-2024-01692 type: OTHER domain: NCI-CTRP Clinical Registry briefTitle: Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms overallStatus: NOT_YET_RECRUITING date: 2024-07-31 date: 2025-12-01 date: 2027-12-01 date: 2024-02-29 date: 2024-04-03 name: M.D. Anderson Cancer Center class: OTHER briefSummary: The goal of Part 1 of this clinical research study is to find the highest tolerable dose of ASTX029 that can be given in combination with ASTX727 to participants who have RAS-mutant MDS or MDS/MPN. The goal of Part 2 of this clinical research study is to learn if the dose of ASTX029 found in Part 1 can help to control the disease when used in combination with ASTX727. conditions: Pathway Mutant Myelodysplastic Syndromes conditions: Myelodysplastic Neoplasm conditions: Myeloproliferative Neoplasm studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NON_RANDOMIZED interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 36 type: ESTIMATED name: ASTX029 name: ASTX727 measure: Safety and adverse events (AEs) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: MD Anderson Cancer Cente city: Houston state: Texas zip: 77030 country: United States name: Guillermo Montalban Bravo, MD role: CONTACT phone: 713-794-3604 email: gmontalban1@mdanderson.org name: Guillermo Montalban Bravo, MD role: PRINCIPAL_INVESTIGATOR lat: 29.76328 lon: -95.36327 hasResults: False
nctId: NCT06284447 id: 22-004500 id: NCI-2024-00181 type: REGISTRY domain: CTRP (Clinical Trial Reporting Program) id: 22-004500 type: OTHER domain: Mayo Clinic Institutional Review Board briefTitle: Barriers to Cervical Cancer Screening overallStatus: RECRUITING date: 2023-03-23 date: 2025-03-31 date: 2025-03-31 date: 2024-02-29 date: 2024-02-29 name: Mayo Clinic class: OTHER briefSummary: This study evaluates barriers to cervical cancer screening among non-compliant women. conditions: Cervical Carcinoma studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: CROSS_SECTIONAL count: 200000 type: ESTIMATED name: Non-Interventional Study measure: Identify barriers to cervical cancer screening sex: FEMALE minimumAge: 21 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Mayo Clinic in Rochester status: RECRUITING city: Rochester state: Minnesota zip: 55905 country: United States name: Clinical Trials Referral Office role: CONTACT phone: 855-776-0015 email: mayocliniccancerstudies@mayo.edu name: Brittany A. Strelow, DSMc, PA-C role: PRINCIPAL_INVESTIGATOR lat: 44.02163 lon: -92.4699 hasResults: False
nctId: NCT06284434 id: CHI2311 briefTitle: Liposomal Bupivacaine Use in Alveolar Bone Graft Patients overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2026-03 date: 2026-03 date: 2024-02-29 date: 2024-03-04 name: Kerry O'Rourke class: OTHER name: Shriners Hospitals for Children briefSummary: The goal of this clinical trial is to learn if a pain medication called liposomal bupivacaine (brand name EXPAREL®) with epinephrine will provide better pain control, increased activity, and reduced use of opioids compared with the standard treatment for patients age 6 years and older with cleft lip and palate who have had an alveolar bone graft surgery. Investigators will look at:
* scores on activity questionnaires Researchers will compare the results of these items with those of patients who had the standard treatment of bupivacaine with epinephrine. conditions: Cleft Lip and Palate studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: The design of this study is a randomized control trial, double-blinded. Patients who meet criteria and consent will be randomized to receive LB or standard bupivacaine. primaryPurpose: SUPPORTIVE_CARE masking: TRIPLE maskingDescription: Surgeons and patients will be unaware of which cohort the subject will be randomized to be part of. The pharmacist, anesthesiologist, and research coordinator may all be aware of which drug is administered. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR count: 60 type: ESTIMATED name: Liposomal Bupivacaine name: Bupivacain name: Epinephrine measure: Visual Analog Pain Scores measure: Opioid Use measure: PROMIS Pediatric Mobility Questionnaire sex: ALL minimumAge: 6 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06284421 id: IRB23-1068 briefTitle: Durometer for Measuring Uterine Tone overallStatus: RECRUITING date: 2024-02-08 date: 2024-06-30 date: 2024-09-30 date: 2024-02-29 date: 2024-03-01 name: University of Chicago class: OTHER briefSummary: This study will evaluate the use of a durometer to measure uterine tone in parturients undergoing cesarean delivery. conditions: Uterine Tone Disorders conditions: Cesarean Section Complications studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: DEVICE_FEASIBILITY masking: NONE count: 20 type: ESTIMATED name: Shore durometer measure: feasibility of a durometer measure: durometer reading measure: durometer reading measure: durometer reading measure: correlation of durometer reading with a 0-10 uterine tone rating score (0= "no tone"; 10= "excellent tone") measure: correlation of durometer reading with a 0-10 uterine tone rating score (0= "no tone"; 10= "excellent tone") measure: correlation of durometer reading with a 0-10 uterine tone rating score (0= "no tone"; 10= "excellent tone") sex: FEMALE minimumAge: 18 Years maximumAge: 50 Years stdAges: ADULT facility: University of Chicago status: RECRUITING city: Chicago state: Illinois zip: 60637 country: United States name: Naida M Cole, MD role: CONTACT phone: 773-702-6700 email: nmcole@bsd.uchicago.edu name: Somayeh Mohammadi role: CONTACT phone: 17738343274 email: mohammadis@bsd.uchicago.edu lat: 41.85003 lon: -87.65005 hasResults: False
nctId: NCT06284395 id: HGM1471-002/24 briefTitle: Two Schemes Response in Multiple Myeloma overallStatus: RECRUITING date: 2023-11-20 date: 2024-03-20 date: 2024-03-30 date: 2024-02-28 date: 2024-02-28 name: Hospital General de Mexico class: OTHER_GOV briefSummary: Retrospective study based on medical records of patients with multiple myeloma, eligible for stem cell transplantation, who received, first-line, the VTD or TD combination. conditions: Response, Acute Phase conditions: Survivorship studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 83 type: ESTIMATED name: Bortezomib measure: Favorable Response measure: Time to next treatment measure: Overall survival sex: ALL minimumAge: 18 Years maximumAge: 90 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Hospital General de Mexico Dr. Eduardo Liceaga status: RECRUITING city: Mexico City state: Cdmx zip: 06720 country: Mexico name: Christian O Ramos Peñafiel, PhD role: CONTACT phone: 5523351588 email: leukemiachop33@gmail.com name: Adan G Gallardo Rodriguez role: CONTACT phone: +525584005072 email: nutriologo.agallardo8@gmail.com name: Juan M Cano Calderón, MD role: SUB_INVESTIGATOR name: Juan F Zazueta Pozos, MD role: SUB_INVESTIGATOR name: Adán G Gallardo Rodriguez, PhD role: SUB_INVESTIGATOR name: Carlos Martínez Murillo, PhD role: SUB_INVESTIGATOR name: Irma Olarte Carrillo, PhD role: SUB_INVESTIGATOR name: Adolfo Martínez Tovar, PhD role: SUB_INVESTIGATOR name: Christian O Ramos Peñafiel, PhD role: PRINCIPAL_INVESTIGATOR lat: 19.42847 lon: -99.12766 hasResults: False
nctId: NCT06284382 id: 2022-A02736-37 briefTitle: Interaction Between Early Trauma and Odor-induced Dopamine Release acronym: T-ODOR overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2026-06-01 date: 2027-06-01 date: 2024-02-28 date: 2024-02-28 name: Hôpital le Vinatier class: OTHER briefSummary: This prospective, double-blind, parallel-group controlled trial aims to investigate the consequence of early trauma on dopamine release evoked by positive valence odors. conditions: Trauma, Psychological studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL interventionModelDescription: This is a prospective, single-center, double-blind, parallel-group controlled trial with two arms. primaryPurpose: BASIC_SCIENCE masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR count: 30 type: ESTIMATED name: High score at Childhood Trauma Questionnaire. name: Low score at Childhood Trauma Questionnaire. measure: Dopamine transmission measured with positron emission tomography measure: Odor hedonic appreciation. measure: Functional brain connectivity. measure: Effective brain connectivity sex: ALL minimumAge: 18 Years maximumAge: 30 Years stdAges: ADULT hasResults: False
nctId: NCT06284369 id: Mongolia briefTitle: Video Messages for Smoking Cessation Campaign overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2025-03 date: 2025-04 date: 2024-02-28 date: 2024-03-04 name: Loma Linda University class: OTHER briefSummary: 240 adult smokers will be recruited. Subjects will be asked to view video messages that encourage smoking cessation. The effect of these videos will be assessed. conditions: Smoking Cessation studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: SINGLE maskingDescription: Participants don't know which video each subject is randomized to whoMasked: PARTICIPANT count: 240 type: ESTIMATED name: Developing, Evaluating and Testing Video Messages for a Smoking Cessation Campaign name: Health Message Framing measure: Message Engagement measure: Readiness to Quit Smoking sex: ALL minimumAge: 18 Years maximumAge: 64 Years stdAges: ADULT hasResults: False
nctId: NCT06284356 id: IRB Session 2022/14 Protocol 6 briefTitle: Pan Immune Inflammation Value for Perioperative Complications of Laparoscopic Sleeve Gastrectomy overallStatus: COMPLETED date: 2022-05-01 date: 2023-05-01 date: 2023-05-01 date: 2024-02-28 date: 2024-03-01 name: Kahramanmaras Sutcu Imam University class: OTHER name: Elazig Special Eastern Anatolian Hospital briefSummary: Morbid obesity emerges as a problem that causes serious complications and increased mortality rates. The most effective treatment for morbid obesity today is surgical treatment. The most preferred type of surgery in morbid obesity surgery in Turkey and around the world is Laparoscopic Sleeve Gastrectomy (LSG).
In this study, the diagnostic importance of changes in NLR, PLR, and PIV values in the preoperative and postoperative periods will be investigated in detecting complications that develop in the perioperative period before discharge in patients who underwent LSG. conditions: Morbid Obesity conditions: Laparoscopic Sleeve Gastrectomy conditions: Post Operative Complicaiton studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 159 type: ACTUAL name: Laparoscopic Sleeve Gastrectomy measure: Complication prediction after LSG with complete blood cell parameters sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Kahramanmaras SIU city: Kahramanmaraş zip: 46000 country: Turkey lat: 37.5847 lon: 36.92641 hasResults: False
nctId: NCT06284343 id: 6414 briefTitle: Development and Validation of a Risk Prediction Model for Venous Thromboembolism in Gynecological Cancer Patients Undergoing Systemic Antineoplastic Treatment: The Gynecological Cancer Associated Thrombosis (GynCAT) Study acronym: GynCAT overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2026-09-30 date: 2026-09-30 date: 2024-02-28 date: 2024-02-28 name: Fondazione Policlinico Universitario Agostino Gemelli IRCCS class: OTHER name: Fondazione Umberto Veronesi briefSummary: Cancer patients are burdened by an increased risk of venous thromboembolism (VTE), which has a significant impact on morbidity and mortality. Existing Risk Prediction Models (RPMs), including the widely accepted Khorana Risk Score (KRS), have some limitations when used in certain tumor site populations, such as gynecological cancers. Notably, gynecological patients exhibit a variable risk of VTE based on their specific tumor sites, with ovarian cancer representing the highest risk. Moreover, currently available RPMs lack validation in a broad gynecological population and may fail to effectively stratify VTE risk.